Circulating miRNAs as Potential Biomarkers for Celiac Disease Development.
autoimmunity
celiac disease
pre-clinical marker
pre-diagnostic marker
small RNA sequencing
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
01
07
2021
accepted:
05
11
2021
entrez:
24
12
2021
pubmed:
25
12
2021
medline:
11
2
2022
Statut:
epublish
Résumé
Celiac disease (CeD), an immune-mediated disease with enteropathy triggered by gluten, affects ~1% of the general European population. Currently, there are no biomarkers to predict CeD development. MicroRNAs (miRNAs) are short RNAs involved in post-transcriptional gene regulation, and certain disease- and stage-specific miRNA profiles have been found previously. We aimed to investigate whether circulating miRNAs can predict the development of CeD. Using next-generation miRNA-sequencing, we determined miRNAs in >200 serum samples from 53 participants of the PreventCD study, of whom 33 developed CeD during follow-up. Following study inclusion at 3 months of age, samples were drawn at predefined ages, diagnosis (first anti-transglutaminase antibody (TGA) positivity or diagnostic biopsy) and after the start of a gluten-free diet (GFD). This allowed identification of circulating miRNAs that are deregulated before TGA positivity. For validation of the biomarkers for CeD and GFD response, two additional cohorts were included in subsequent meta-analyses. Additionally, miRNAs were measured in duodenal biopsies in a case-control cohort. 53 circulating miRNAs were increased (27) or decreased (26) in CeD We identified 53 circulating miRNAs that are potential early biomarkers for CeD, of which several can be detected more than a year before TGA positivity and some start to normalize upon GFD.
Sections du résumé
Background & Aims
Celiac disease (CeD), an immune-mediated disease with enteropathy triggered by gluten, affects ~1% of the general European population. Currently, there are no biomarkers to predict CeD development. MicroRNAs (miRNAs) are short RNAs involved in post-transcriptional gene regulation, and certain disease- and stage-specific miRNA profiles have been found previously. We aimed to investigate whether circulating miRNAs can predict the development of CeD.
Methods
Using next-generation miRNA-sequencing, we determined miRNAs in >200 serum samples from 53 participants of the PreventCD study, of whom 33 developed CeD during follow-up. Following study inclusion at 3 months of age, samples were drawn at predefined ages, diagnosis (first anti-transglutaminase antibody (TGA) positivity or diagnostic biopsy) and after the start of a gluten-free diet (GFD). This allowed identification of circulating miRNAs that are deregulated before TGA positivity. For validation of the biomarkers for CeD and GFD response, two additional cohorts were included in subsequent meta-analyses. Additionally, miRNAs were measured in duodenal biopsies in a case-control cohort.
Results
53 circulating miRNAs were increased (27) or decreased (26) in CeD
Conclusions
We identified 53 circulating miRNAs that are potential early biomarkers for CeD, of which several can be detected more than a year before TGA positivity and some start to normalize upon GFD.
Identifiants
pubmed: 34950132
doi: 10.3389/fimmu.2021.734763
pmc: PMC8688806
doi:
Substances chimiques
Biomarkers
0
Circulating MicroRNA
0
Types de publication
Journal Article
Meta-Analysis
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
734763Informations de copyright
Copyright © 2021 Tan, Coutinho de Almeida, Modderman, Stachurska, Dekens, Barisani, Meijer, Roca, Martinez-Ojinaga, Shamir, Auricchio, Korponay-Szabó, Castillejo, Szajewska, Koletzko, Zhernakova, Kumar, Li, Visschedijk, Weersma, Troncone, Mearin, Wijmenga, Jonkers and Withoff.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Sci Rep. 2019 Nov 7;9(1):16163
pubmed: 31700112
Nucleic Acids Res. 2017 Sep 19;45(16):9290-9301
pubmed: 28934507
Medicine (Baltimore). 2015 Sep;94(38):e1612
pubmed: 26402826
Aliment Pharmacol Ther. 2012 Mar;35(5):540-51
pubmed: 22239821
Front Immunol. 2014 Oct 20;5:513
pubmed: 25368617
Gut. 2017 Feb;66(2):250-257
pubmed: 26608460
Nat Rev Clin Oncol. 2011 Jun 07;8(8):467-77
pubmed: 21647195
Expert Rev Gastroenterol Hepatol. 2016 Jul;10(7):795-805
pubmed: 26838683
Biomed Res Int. 2020 Jul 22;2020:4250329
pubmed: 32775420
Front Genet. 2021 Jan 25;11:562434
pubmed: 33569077
Nat Rev Gastroenterol Hepatol. 2015 Sep;12(9):527-36
pubmed: 26100369
Gut. 2014 Aug;63(8):1210-28
pubmed: 24917550
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8
pubmed: 18663219
J Breath Res. 2013 Sep;7(3):037104
pubmed: 23774130
Cell. 2019 Feb 21;176(5):967-981.e19
pubmed: 30739797
Nucleic Acids Res. 2015 Jul 1;43(W1):W460-6
pubmed: 25977294
Gastroenterology. 2017 Oct;153(4):924-935
pubmed: 28624578
Nucleic Acids Res. 2019 Jan 8;47(D1):D155-D162
pubmed: 30423142
Clin Transl Gastroenterol. 2019 May 22;10(5):1-10
pubmed: 31082858
United European Gastroenterol J. 2019 May;7(4):467-476
pubmed: 31065364
Nat Rev Dis Primers. 2019 Jan 10;5(1):3
pubmed: 30631077
Genes Nutr. 2015 Sep;10(5):482
pubmed: 26233308
World J Gastroenterol. 2017 Aug 7;23(29):5324-5332
pubmed: 28839432
J Pediatr Gastroenterol Nutr. 2011 Jul;53(1):26-33
pubmed: 21546856
Sci Rep. 2019 Oct 4;9(1):14303
pubmed: 31586100
Clin Gastroenterol Hepatol. 2018 Jun;16(6):823-836.e2
pubmed: 29551598
Cell Rep. 2018 Oct 30;25(5):1346-1358
pubmed: 30380423
United European Gastroenterol J. 2018 May;6(4):567-575
pubmed: 29881612
Cells. 2020 Feb 24;9(2):
pubmed: 32102433
Gastroenterology. 2015 May;148(6):1175-86
pubmed: 25662623
Dig Dis Sci. 2020 Jul;65(7):1982-1991
pubmed: 31781909
PLoS One. 2011;6(12):e29094
pubmed: 22194996
Clin Exp Immunol. 2013 Aug;173(2):250-8
pubmed: 23607522
Gut. 2012 Sep;61(9):1355-64
pubmed: 21890812
J Pediatr Gastroenterol Nutr. 2012 Jan;54(1):136-60
pubmed: 22197856
Nat Rev Endocrinol. 2013 Sep;9(9):513-21
pubmed: 23629540
Eur Ann Allergy Clin Immunol. 2019 Jul;51(4):159-164
pubmed: 30983306
Eur J Gastroenterol Hepatol. 2010 Dec;22(12):1424-30
pubmed: 21389794
Nat Rev Gastroenterol Hepatol. 2015 Sep;12(9):507-15
pubmed: 26303674
Gastroenterology. 2007 Mar;132(3):994-1008
pubmed: 17324400
Nat Rev Mol Cell Biol. 2019 Jan;20(1):21-37
pubmed: 30108335
Nat Rev Immunol. 2015 Dec;15(12):771-83
pubmed: 26567920
Cell Res. 2008 Oct;18(10):997-1006
pubmed: 18766170
Am J Gastroenterol. 2014 Oct;109(10):1662-74
pubmed: 25070052
J Pediatr Gastroenterol Nutr. 2017 Sep;65(3):314-320
pubmed: 28827480
Rev Esp Enferm Dig. 2014 May;106(5):325-33
pubmed: 25287235
Clin Sci (Lond). 2014 Mar;126(6):417-23
pubmed: 24063611
Genome Med. 2016 Apr 21;8(1):45
pubmed: 27102333
Dig Liver Dis. 2016 May;48(5):499-505
pubmed: 26854256
PLoS One. 2013 Jun 24;8(6):e66814
pubmed: 23826144
N Engl J Med. 2014 Oct 2;371(14):1304-15
pubmed: 25271603